INO-3107 · Voceryq

Gene therapy / editing

Approvedregulatory verdict

Evidence outlook

Approved: Recurrent Respiratory Papillomatosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Recurrent Respiratory Papillomatosis

Competitive landscape

This drug's own stage for Recurrent Respiratory Papillomatosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
INO-3107 (Voceryq): this drugApprovedGene therapy / editingHPV-6 and HPV-11 antigensWeak signalFeatured results are safety only in this race
Zopapogene Imadenovec (Papzimeos)ApprovedGene therapy / editingHPV6/HPV11 antigens (immunotherapy)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 November 2026Filing submittedConditional MAA submitted to EMA for VOCERYQ
EU, EMA · Source ↗
30 October 2026FDA action datePDUFA goal date for the INO-3107 BLA in RRP
US, FDA · FDA · Source ↗
30 October 2026ApprovalFDA grants accelerated approval to Voceryq (INO-3107) in RRP
US, FDA · Source ↗
29 December 2025Filing acceptedFDA accepts INOVIO's BLA for INO-3107 in adults with RRP (standard review, accelerated approval pathway)
US, FDA · Inovio Pharmaceuticals, Inc. · Source ↗
3 November 2025Filing submittedINOVIO completes the rolling BLA submission for INO-3107 (accelerated approval)
US, FDA · Inovio Pharmaceuticals, Inc. · Source ↗